吉林敖东(000623) - 2019 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2019 was ¥3,088,379,591.97, a decrease of 7.09% compared to ¥3,324,078,265.78 in 2018[8]. - Net profit attributable to shareholders for 2019 was ¥1,403,640,313.56, representing a 50.09% increase from ¥935,187,893.18 in 2018[8]. - The net profit after deducting non-recurring gains and losses was ¥1,277,462,446.54, up 45.43% from ¥878,430,261.44 in the previous year[8]. - Basic earnings per share for 2019 were ¥1.2070, an increase of 50.07% compared to ¥0.8043 in 2018[8]. - The total operating revenue for the company in 2019 was RMB 3,088,379,591.97, representing a decrease of 7.09% compared to RMB 3,324,078,265.78 in 2018[34]. - The net profit attributable to shareholders was CNY 140,364.03 million, an increase of CNY 46,845.24 million or 50.09% year-on-year[22]. - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2019, representing a year-over-year increase of 10%[147]. - The net profit for the year was 300 million RMB, which is a 15% increase compared to the previous year[147]. Assets and Liabilities - Total assets at the end of 2019 were ¥25,800,904,916.27, a 4.63% increase from ¥24,658,542,292.54 at the end of 2018[8]. - Net assets attributable to shareholders at the end of 2019 were ¥22,249,498,565.07, reflecting a 5.81% increase from ¥21,028,405,792.95 in 2018[8]. - The total assets of the company at the end of 2019 were ¥25.80 billion, with net assets of ¥22.44 billion[15]. - The asset-liability ratio stands at 13.01%, indicating a strong financial position[22]. - The company's total assets-liabilities ratio as of December 31, 2019, was 13.01%, a decrease from 13.85% in 2018, indicating strong debt repayment capability[181]. Cash Flow - The company reported a net cash flow from operating activities of ¥379,456,901.57, an increase of 9.15% from ¥347,635,221.58 in 2018[8]. - The total cash inflow from operating activities in 2019 was CNY 3,521,658,072.52, a decrease of 4.53% compared to 2018[5]. - The net cash flow from investment activities turned positive at CNY 157,887,970.79, a 109.00% increase compared to the previous year[5]. - Cash and cash equivalents increased by CNY 275,722,053.55, a decrease of 62.04% year-on-year[5]. Investments and Acquisitions - The company invested CNY 8,244.17 million in the automation production line project, which has commenced production[25]. - The company completed the acquisition of Auscon Biopharmaceuticals with an investment of CNY 12 million, holding a 1.39% stake[52]. - The company invested CNY 152.47 million in various self-built projects, with a cumulative actual investment of CNY 259.17 million by the end of the reporting period[53]. - The company plans to invest 100 million yuan in R&D for new technologies over the next two years[140]. Research and Development - R&D efforts include the development of new drugs and classic formulas, with ongoing projects for various treatments including pancreatic and lung cancer[26]. - Research and development expenses rose by 62.52% to 142,897,914.24 yuan, primarily due to increased product development spending by subsidiaries[43]. - The company aims to enhance its core competitiveness through continuous investment in talent development and training programs[32]. Market and Sales - The pharmaceutical segment generated RMB 2,897,045,013.07, accounting for 93.80% of total revenue, with an 8.61% decline from RMB 3,170,006,912.71 in the previous year[34]. - The food segment revenue increased by 31.76% to RMB 131,045,206.69, compared to RMB 99,460,290.59 in 2018[34]. - The total sales volume for the pharmaceutical sector decreased by 1.86% to 106,696,920 boxes in 2019 compared to 2018[36]. - The production volume for food increased by 57.70% to 11,382,853 boxes in 2019, driven by the growth of the subsidiary Jilin Aodong Health Technology Co., Ltd.[36]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of ¥2 per 10 shares to all shareholders[2]. - The total cash dividend amount for 2019 is 232,607,090.80 CNY, which represents 16.57% of the net profit attributable to ordinary shareholders[83]. - The cash dividend total for 2019 represents 100% of the total distributable profits[85]. Corporate Governance - The company has established a robust investor relations management system to enhance communication with investors[157]. - The company operates independently from its controlling shareholder in business, personnel, assets, institutions, and finance[159]. - The company’s board of directors is responsible for establishing and maintaining effective internal controls as per regulatory requirements[172]. Environmental and Social Responsibility - The company has invested over 60 million RMB in wastewater treatment facilities over the past three years, achieving a maximum daily treatment capacity of 8,000 tons[110]. - The company has actively integrated ecological and environmental protection requirements into its development strategy and governance processes[110]. - A total of 28 million yuan was allocated for poverty alleviation efforts, helping 225 registered impoverished individuals to escape poverty[106]. Future Outlook - The company provided a future outlook, projecting a revenue growth of 10% for the next fiscal year[136]. - The company has set a revenue guidance of 1.8 billion RMB for the fiscal year 2020, projecting a growth of 20%[147]. - The company plans to enhance its digital marketing efforts, aiming for a 30% increase in online sales channels[147].